Anticholinesterase and Serotoninergic Evaluation of Benzimidazole–Carboxamides as Potential Multifunctional Agents for the Treatment of Alzheimer’s Disease

Simple item page
dc.contributor.authorBelinskaia, D.A.
dc.contributor.authorVoronina, P.A.
dc.contributor.authorKrivorotov, D.V.
dc.contributor.authorJenkins, R.O.
dc.contributor.authorGoncharov, N. V.
dc.date.acceptance2023-08-17
dc.date.accessioned2024-04-15T12:16:42Z
dc.date.available2024-04-15T12:16:42Z
dc.date.issued2023-08-19
dc.descriptionopen access article
dc.description.abstractThe etiology and pathogenesis of Alzheimer’s disease are multifactorial, so one of the treatment strategies is the development of the drugs that affect several targets associated with the pathogenesis of the disease. Within this roadmap, we investigated the interaction of several substituted 1,3-dihydro-2-oxo-1H-benzimidazol-2-ones with their potential molecular targets: cholinesterases (ChE) and three types of the Gs-protein-coupled serotonin receptors (5-HTR) 5-HT6, 5-HT4 and 5-HT7 (5-HT4R, 5-HT6R and 5-HT7R, respectively). A microplate modification of the Ellman method was used for the biochemical analysis of the inhibitory ability of the drugs towards ChE. Molecular modeling methods, such as molecular docking and molecular dynamics (MD) simulation in water and the lipid bilayer, were used to study the interaction of the compounds with ChE and 5-HTR. In vitro experiments showed that the tested compounds had moderate anticholinesterase activity. With the help of molecular modeling methods, the mechanism of interaction of the tested compounds with ChE was investigated, the binding sites were described and the structural features of the drugs that determine the strength of their anticholinesterase activity were revealed. Primary in silico evaluation showed that benzimidazole–carboxamides effectively bind to 5-HT4R and 5-HT7R. The pool of the obtained data allows us to choose N-[2-(diethylamino)ethyl]-2-oxo-3-(tert-butyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide hydrochloride (compound 13) as the most promising for further experimental development.
dc.funderNo external funder
dc.identifier.citationBelinskaia, D.A., Voronina, P.A., Krivorotov, D.V., Jenkins, R.O. and Goncharov, N.V. (2023) Anticholinesterase and Serotoninergic Evaluation of Benzimidazole–Carboxamides as Potential Multifunctional Agents for the Treatment of Alzheimer’s Disease. Pharmaceutics, 15 (8), 2159
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics15082159
dc.identifier.issn1999-4923
dc.identifier.urihttps://hdl.handle.net/2086/23693
dc.language.isoen
dc.peerreviewedYes
dc.publisherMDPI
dc.relation.ispartofseries15082159
dc.researchinstituteInstitute for Allied Health Sciences Research
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleAnticholinesterase and Serotoninergic Evaluation of Benzimidazole–Carboxamides as Potential Multifunctional Agents for the Treatment of Alzheimer’s Disease
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PUBLISHED_Alzheimer's.pdf
Size:
10.3 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.2 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

School of Allied Health Sciences